Adamis Pharmaceuticals reported $-7807550 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Brainstorm Cell Therapeutics BCLI:US USD -6771000 749K
Cara Therapeutics CARA:US USD -23783000 19.37M
GlaxoSmithKline GSK:LN GBP 3.36B 916M
Glaxosmithkline GSK:US GBP 3.36B 916M
Pfizer PFE:US USD 10.52B 2.78B